Evidence Base
Featured Topics
Lead story
Other featured articles
-
A COVID Takeaway for California: Data Needs to Drive Health Policy
A key lesson from the pandemic is that the state needs to get a better handle on economic trade-offs as it implements preventive measures, especially vaccines.
Posted in -
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on their Effects.
Policymakers should proceed with caution as they design proposals to restrict advertising.
Posted in -
Two Percent of U.S. Children Receive High Quality Tutoring, Despite Billions Funneled into School Systems
We are far from the goal of providing high-quality tutoring to all who need it.
Posted in -
Eli Lilly Is Cutting Insulin Prices and Capping Copays at $35 – 5 Questions Answered
The drugmaker’s move responded to the growing competition that has shaken up the insulin market in recent years.
Posted in
About this section
The Evidence Base focuses on improving policy in health, economics, and well-being. Learn More>
View all of the contributors to The Evidence Base here.
More from the Evidence Base Blog
-
COVID-19’s Total Cost to the U.S. Economy Will Reach $14 Trillion by End of 2023
Workplace absences, along with sales lost due to the cessation of brick-and-mortar retail shopping, airline travel and public gatherings, contributed the most.
Categorized in -
Should the Government Restrict Direct-to-Consumer Prescription Drug Advertising? Six Takeaways on their Effects.
Policymakers should proceed with caution as they design proposals to restrict advertising.
Categorized in -
Hidden Physician Financial Conflicts of Interest in Dialysis
Nephrologists’ ownership of dialysis facilities doesn’t affect outcomes, but why is it so secret?
Categorized in -
National Survey Findings Shed Light on Dimensions of Teen Mental Health Concerns
We find evidence of worsening mental health since 2013 among both boys and girls.
Categorized in -
CMS’s Alzheimer’s Coverage Policy Will Inhibit Access and Discourage Innovation
Individuals in underserved communities have to travel long distances, well beyond the 30-minute standard, to access clinical trial sites for Aduhelm.
Categorized in